Details
Synopsis
Dr. Brian Holbrook thinks he can keep his life under control--as long as he continues to prescribe himself high doses of painkillers. But his secret is soon discovered, and he loses his medical licence and his job. Then Brian is offered a job at the Boston Heart Institute researching a miracle drug, and he thinks his prayers have been answered. Brian is mistaken.
| Size | | Length: | 399 pages | | Height: | 10.0 in | | Width: | 6.5 in | | Thickness: | 1.5 in | | Weight: | 24.8 oz |
Industry Reviews
A disgraced doctor finds himself working in an experimental program where patients are dying mysteriously.
Moore
In this flawed medical thriller about the marketing of a new drug by veteran writer Palmer (The Sisterhood), one plot twist too many turns a frightening vision of corporate greed into an excuse for prefab heroics. The drug is called Vasclear, a heart medication being developed at the Boston Heart Institute by Newbury Pharmaceuticals. The FDA is being pressured by a Massachusetts senator (who, it turns out, is secretly taking Vasclear himself) to approve the release of the drug. And Vasclear may be the magic wand that can save the life of Jack "Coach" Holbrook, whose health is declining after a quintuple bypass. Coach's son, Brian (an M.D. living at home and working as a rental-car gofer while he recovers from an addiction to painkillers), not only faces the ethical dilemma of stealing the drug if he can't place his father as a test patient but also finds evidence of potentially dangerous side effects evidence that could derail the drug's release to the public. The characters are sitcom thin, the moral dilemma is barely raised before it's resolved and the inclusion of a Chechen Mafia subplot only serves to transport the story further into an unlikely realm, where otherwise efficient killers do nothing more dangerous than send the hero a threat in the mail and members of drug and alcohol recovery groups know more about pharmaceutical companies than the FDA. Palmer's thriller-friendly prose, pacing and plotting draw readers on here, but, like Vasclear, his novel should have spent more time in development before it hit the shelves. (Mar.)
Lopate
|
All rights reserved.
